Highlights
– TALAPRO-2 final analyses show a statistically significant overall survival (OS) benefit when talazoparib is added to enzalutamide in men with metastatic castration‑resistant prostate cancer (mCRPC), both in HRR‑deficient and unselected populations.
– The survival advantage is most pronounced in patients with BRCA1/2 alterations (HR ~0.50 in HRR‑deficient cohort; HR 0.55 in unselected HRR‑deficient subgroup), with a doubling of 4‑year OS in the BRCA subgroup.